Form 4: Virios Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Abel De La Rosa acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.
Summary
- On February 26, 2024, Abel De La Rosa, a director of Virios Therapeutics, Inc., acquired 3,959 stock options.
- The exercise price of these options is $0.357.
- The options vest 100% on February 26, 2025, and expire on February 26, 2034.
- Following the transaction, De La Rosa directly owns 3,959 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. A director acquiring stock options is a routine occurrence and doesn't necessarily indicate positive or negative sentiment.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of transaction: Abel De La Rosa acquired stock options. |
| 02/26/2025 | Vesting date: Stock options vest 100%. |
| 02/26/2034 | Expiration date: Stock options expire. |
| 02/28/2024 | Date of signature. |
Keywords
stock options, Form 4, Virios Therapeutics, VIRI, director, insider trading, Abel De La Rosa
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.